Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation

Liver Transplantation

Volumn 16, Issue 10, 2010, Pages 1136-1146

  Ichai, Philippe ^a,b,c   Saliba, Faouzi ^a,b,c   Antoun, Fadi ^a   Azoulay, Daniel ^a,b   Sebagh, Mylène ^a,b,c   Antonini, Teresa Maria ^a,b   Escaut, Lélia ^a   Delvart, Valérie ^a   Castaing, Denis ^a,b,c   Samuel, Didier ^a,b,c  

^a HÔPITAL PAUL BROUSSE   (France)

^b Universite Paris Sud   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ETHAMBUTOL; ISONIAZID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACUTE LIVER FAILURE; ADULT; CLINICAL ARTICLE; DRUG TOLERANCE; FEMALE; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; REVIEW; SURVIVAL; TREATMENT PLANNING; TUBERCULOSIS; ADOLESCENT; ARTICLE; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; DRUG COMBINATION; FRANCE; GRAFT REJECTION; MIDDLE AGED; MORTALITY; REMISSION; RISK ASSESSMENT; RISK FACTOR; TIME; TOXIC HEPATITIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; FRANCE; GRAFT REJECTION; HUMANS; ISONIAZID; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; REMISSION, SPONTANEOUS; RIFAMPIN; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 79952114997     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22125     Document Type: Review

References (52)

1. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167: 603-662.
2. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975;69:289-302.
3. Moulding TS, Redeker AG, Kanel GC. Twenty isoniazidassociated deaths in one state. Am Rev Respir Dis 1989; 140:700-705.
4. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis 1972;106:357-365.
5. Durand F, Bernuau J, Pessayre D, Samuel D, Belaiche J, Degott C, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995;21:929-932.
6. Meyers BR, Papanicolaou GA, Sheiner P, Emre S, Miller C. Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens. Transplantation 2000;69:64-69.
7. Clemente WT, Faria LC, Lima SS, Vilela EG, Lima AS, Velloso LF, et al. Tuberculosis in liver transplant recipients: a single Brazilian center experience. Transplantation 2009;87:397-401.
8. Idilman R, Ersoz S, Coban S, Kumbasar O, Bozkaya H. Antituberculous therapy-induced fulminant hepatic failure: successful treatment with liver transplantation and nonstandard antituberculous therapy. Liver Transpl 2006;12:1427-1430.
9. Rastogi N, Goh KS, Bryskier A, Devallois A. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Antimicrob Agents Chemother 1996;40:2483-2487.
10. Kennedy N, Berger L, Curram J, Fox R, Gutmann J, Kisyombe GM, et al. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22:827-833.
11. Crowle AJ, Elkins N, May MH. Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium and rifampin against M. tuberculosis in cultured human macrophages. Am Rev Respir Dis 1988;137: 1141-1146.
12. Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, Cegielski JP. Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA 2008;300:2153-2160.
13. Ho CC, Chen YC, Hu FC, Yu CJ, Yang PC, Luh KT. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clin Infect Dis 2009;48:1526-1533.
14. Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother 2003;15:66-70.
15. Hutchison DC, Drobniewski FA, Milburn HJ. Management of multiple drug-resistant tuberculosis. Respir Med 2003;97:65-70.
16. Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2003;47:3117-3122.
17. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007;67:2077-2099.
18. Bismuth H, Samuel D, Castaing D, Adam R, Saliba F, Johann M, et al. Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience. Ann Surg 1995;222:109-119.
19. Williams R, Gimson AE. Intensive liver care and management of acute hepatic failure. Dig Dis Sci 1991;36: 820-826.
20. Bernuau J, Durand F, Werner P, Sauvanet A, Erlinger S, Belghiti J. Acute liver failure. Lancet 1995;345:802.
21. Trey C, Davidson CS. The management of fulminant hepatic failure. In: Popper H, Shaffner F, eds. Progress in Liver Diseases: The Management of Fulminant Hepatic Failure. New York, NY: Grune & Stratton 1970: 282-298.
22. Williams R, Wendon J. Indications for orthotopic liver transplantation in fulminant liver failure. Hepatology 1994;20:S5-10S.
23. Bernuau J, Goudeau A, Poynard T, Dubois F, Lesage G, Yvonnet B, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986;6:648-651.
24. Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins. ASAIO J 1993;39: M621-M625.
25. Saliba F, Camus C, Durand F, Mathurin P, Delafosse B, Barange K, et al. Randomized controlled multicenter trial evaluating the efficacy and safety of albumin dialysis with MARSVR in patients with fulminant and subfulminant hepatic failure [abstract]. Hepatology 2008;48: 377A.
26. Samuel D, Ichai P, Feray C, Saliba F, Azoulay D, Arulnaden JL, et al. Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation. Transplantation 2002;73: 257-264.
27. Demetriou AA, Brown RS Jr, Busuttil RW, Fair J, McGuire BM, Rosenthal P, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004;239:660-667.
28. Aguado JM, Herrero JA, Gavalda J, Torre-Cisneros J, Blanes M, Rufi G, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997; 63:1278-1286.
29. Faria L, Ichai P, Saliba F, Azoulay D, Antonini T, Ben Hamida S, et al. Etiology, outcome and early causes of death in 500 patients with acute liver failure: 20 year single center experience [abstract]. Hepatology 2006;44: 370A.
30. Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl 2009;15:719-729.
31. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996;22:211-214.
32. Tahaoglu K, Atac G, Sevim T, Tarun T, Yazicioglu O, Horzum G, et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2001;5:65-69.
33. Sharma SK, Singla R, Sarda P, Mohan A, Makharia G, Jayaswal A, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010;50:833-839.
34. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998;27: 1266-1277.
35. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991;99: 465-471.
36. Schluger LK, Sheiner PA, Jonas M, Guarrera JV, Fiel IM, Meyers B, Berk PD. Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J Med 1996;63: 364-369.
37. Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl 2009;15:894-906.
38. Barcena R, Oton E, Angeles Moreno M, Fortun J, Garcia-Gonzalez M, Moreno A, de Vicente E. Is liver transplantation advisable for isoniazid fulminant hepatitis in active extrapulmonary tuberculosis? Am J Transplant 2005;5: 2796-2798.
39. Chan AC, Lo CM, Ng KK, Chan SC, Fan ST. Implications for management of Mycobacterium tuberculosis infection in adult-to-adult live donor liver transplantation. Liver Int 2007;27:81-85.
40. Wang B, Lu Y, Liu C, Liu X, Wu Z, Zhu HT, Pan CE. Liver transplantation for patients with pulmonary tuberculosis. Transpl Infect Dis 2009;11:128-131.
41. Kunin CM. Antimicrobial activity of rifabutin. Clin Infect Dis 1996;22(SUPPL. 1):S3-S13.
42. Lopez-Montes A, Gallego E, Lopez E, Perez J, Lorenzo I, Llamas F, et al. Treatment of tuberculosis with rifabutin in a renal transplant recipient. Am J Kidney Dis 2004; 44:e59-e63.
43. Munoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005;40:581-587.
44. Farrell FJ, Keeffe EB, Man KM, Imperial JC, Esquivel CO. Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation. Dig Dis Sci 1994;39: 2255-2259.
45. Pessayre D, Bentata M, Degott C, Nouel O, Miguet JP, Rueff B, Benhamou JP. Isoniazid-rifampin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction. Gastroenterology 1977;72:284-289.
46. Mitchell I, Wendon J, Fitt S, Williams R. Anti-tuberculous therapy and acute liver failure. Lancet 1995;345: 555-556.
47. Marra F, Cox VC, FitzGerald JM, Moadebi S, Elwood RK. Successful treatment of multidrug-resistant tuberculosis following drug-induced hepatic necrosis requiring liver transplant. Int J Tuberc Lung Dis 2004;8:905-909.
48. Cillo U, Bassanello M, Vitale A, D'Antiga L, Zanus G, Brolese A, et al. Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver's early regeneration after auxiliary partial orthotopic liver transplantation. Transpl Int 2005;17:713-716.
49. Campos-Franco J, Gonzalez-Quintela A, Alende-Sixto MR. Isoniazid-induced hyperacute liver failure in a young patient receiving carbamazepine. Eur J Intern Med 2004;15:396-397.
50. Nash KL, Yeung TM, Lehner PJ, Gibbs P, Griffiths WJ. Orthotopic liver transplantation for subacute hepatic failure following partial treatment of isoniazid-resistant tuberculosis. Transpl Infect Dis 2008;10:272-275.
51. Torre-Cisneros J, Caston JJ, Moreno J, Rivero A, Vidal E, Jurado R, Kindelan JM. Tuberculosis in the transplant candidate: importance of early diagnosis and treatment. Transplantation 2004;77:1376-1380.
52. Torre-Cisneros J, Doblas A, Aguado JM, San Juan R, Blanes M, Montejo M, et al. Tuberculosis after solidorgan transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009;48:1657-1665.